MaMome

Mamome specializes in leveraging microbiome analysis and machine learning technologies to improve maternal health outcomes. The company focuses on the early detection of high-risk pregnancies, including those at risk of gestational diabetes, aiming to revolutionize maternal health care. By analyzing the microbiome, Mamome identifies expecting mothers who may face complications during pregnancy, providing a proactive approach to managing and mitigating these risks. The integration of biotechnology and digital health tools allows for personalized care plans, aiming to reduce the incidence of pregnancy-related complications and ensure better health outcomes for both mothers and their babies.

MaMome headquartered in New York, United States, North America, operates in the Biotechnology, Health Care, Medical Device sector. The company focuses on Biotechnology and has secured $3.6M in funding across 12 round(s). With a team of 1-10 employees, MaMome is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - MaMome, raised $300.0K. Discover more about their projects, partnerships, and impact on our platform.